Cancer and Heart Failure: Dangerous Liaisons

Overview

Journal J Cardiovasc Dev Dis

Specialty Cardiology & Vascular Diseases

Date 2024 Sep 27

PMID 39330321

Authors

Davide Bertolini

Carmine Pizzi

Erwan Donal

Elena Galli

Affiliations

Soon will be listed here.

Abstract

Cancer and heart failure (HF) are increasingly relevant worldwide, both from an epidemiologic and clinical point of view. This review aims to explore the relationship between cancer and HF by underscoring risk factors and disclosing the cardiotoxic effects of the current chemotherapy agents. We also deal with the current evidence on the diagnosis and management of HF related to cancer therapy. Finally, we will address the main gaps in knowledge and future perspectives in this field.

Citing Articles

Cardiotoxicity of Chemotherapy: A Multi-OMIC Perspective.

Ma Y, Grootaert M, Sewduth R J Xenobiot. 2025; 15(1.

PMID: 39846541 PMC: 11755476. DOI: 10.3390/jox15010009.

Cardiometabolic Index is associated with heart failure: a cross-sectional study based on NHANES.

Zhu X, Xu Y, Zhang J Front Med (Lausanne). 2024; 11:1507100.

PMID: 39717172 PMC: 11663657. DOI: 10.3389/fmed.2024.1507100.

References

Oeffinger K, Mertens A, Sklar C, Kawashima T, Hudson M, Meadows A . Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006; 355(15):1572-82. DOI: 10.1056/NEJMsa060185. View

Choueiri T, Mayer E, Je Y, Rosenberg J, Nguyen P, Azzi G . Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011; 29(6):632-8. DOI: 10.1200/JCO.2010.31.9129. View

Meijers W, Maglione M, Bakker S, Oberhuber R, Kieneker L, de Jong S . Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation. 2018; 138(7):678-691. DOI: 10.1161/CIRCULATIONAHA.117.030816. View

Armenian S, Hudson M, Mulder R, Chen M, Constine L, Dwyer M . Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015; 16(3):e123-36. PMC: 4485458. DOI: 10.1016/S1470-2045(14)70409-7. View

Araujo-Gutierrez R, Chitturi K, Xu J, Wang Y, Kinder E, Senapati A . Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity. Cardiooncology. 2021; 7(1):4. PMC: 7849080. DOI: 10.1186/s40959-021-00090-2. View

Akinyemiju T, Wiener H, Pisu M . Cancer-related risk factors and incidence of major cancers by race, gender and region; analysis of the NIH-AARP diet and health study. BMC Cancer. 2017; 17(1):597. PMC: 5577755. DOI: 10.1186/s12885-017-3557-1. View

Meijers W, de Boer R . Common risk factors for heart failure and cancer. Cardiovasc Res. 2019; 115(5):844-853. PMC: 6452432. DOI: 10.1093/cvr/cvz035. View

de Azambuja E, Bedard P, Suter T, Piccart-Gebhart M . Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?. Target Oncol. 2009; 4(2):77-88. DOI: 10.1007/s11523-009-0112-2. View

Pudil R, Mueller C, Celutkiene J, Henriksen P, Lenihan D, Dent S . Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020; 22(11):1966-1983. DOI: 10.1002/ejhf.2017. View

10.

Vaduganathan M, Patel R, Michel A, Shah S, Senni M, Gheorghiade M . Mode of Death in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2017; 69(5):556-569. DOI: 10.1016/j.jacc.2016.10.078. View

11.

Glen C, Tan Y, Waterston A, Evans T, Jones R, Petrie M . Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: State-of-the-Art Review. JACC CardioOncol. 2022; 4(1):1-18. PMC: 9040125. DOI: 10.1016/j.jaccao.2022.01.096. View

12.

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni C, Veglia F . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777. View

13.

Motzer R, Hutson T, Cella D, Reeves J, Hawkins R, Guo J . Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369(8):722-31. DOI: 10.1056/NEJMoa1303989. View

14.

Mousavi N, Tan T, Ali M, Halpern E, Wang L, Scherrer-Crosbie M . Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging. 2015; 16(9):977-84. DOI: 10.1093/ehjci/jev113. View

15.

Pitt B, Pfeffer M, Assmann S, Boineau R, Anand I, Claggett B . Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370(15):1383-92. DOI: 10.1056/NEJMoa1313731. View

16.

Armenian S, Xu L, Ky B, Sun C, Farol L, Pal S . Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016; 34(10):1122-30. PMC: 7357493. DOI: 10.1200/JCO.2015.64.0409. View

17.

Mincu R, Mahabadi A, Michel L, Mrotzek S, Schadendorf D, Rassaf T . Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019; 2(8):e198890. PMC: 6692687. DOI: 10.1001/jamanetworkopen.2019.8890. View

18.

Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J . Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020; 8(1). PMC: 7057417. DOI: 10.1136/jitc-2019-000261. View

19.

Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, DAscenzo F, Malavasi V . Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013; 112(12):1980-4. DOI: 10.1016/j.amjcard.2013.08.026. View

20.

Alizadehasl A, Ghadimi N, Kaveh S, Maleki M, Ghavamzadeh A, Noohi F . Prevention of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis. Int J Clin Pharm. 2020; 43(1):25-34. DOI: 10.1007/s11096-020-01146-6. View